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 Abstract 
 Objective: To investigate the efficacy and safety of increasing doses of cathine (nor-pseudo-
ephedrine) as a weight-lowering agent in patients with obesity.  Methods: Overweight and 
obese patients (n = 241, mean BMI 34.6 ± 3.4 kg/m²) were randomly allocated to one of three 
doses of cathine (16 mg, 32 mg, 53.3 mg) or placebo in addition to a multimodal lifestyle in-
tervention program in a multicenter, double-blind, controlled, dose-finding study for 24 
weeks. Primary outcome was weight loss.  Results: Treatment with the 3 doses of cathine re-
sulted in a significantly greater weight loss compared to placebo over 24 weeks: 6.5 ± 4.2 kg 
for 16 mg cathine, 6.2 ± 4.7 kg for 32 mg cathine, and 9.1 ± 5.4 kg for 53.3 mg cathine versus 
2.4 ± 4.4 kg for placebo (each p < 0.01, ANCOVA). The percentage of patients losing > 5% / 
>10% of initial body weight was significantly greater for all doses of cathine than for placebo 
(each p < 0.01, chi-square test). Heart rate increased dose-dependently (by 1.2 bpm under 16 
mg, 5.8 bpm under 32 mg, and 6.2 bpm under 53.3 mg cathine), but no suspected unexpect-
ed serious adverse reactions were noted. The overall dropout rate was 24.9%, with the highest 
rate in the placebo group (42.3%).  Conclusion: Cathine appears to be an effective weight-
lowering agent for adjunct treatment of obesity, but additional clinical studies on its efficacy 
and safety are required.   © 2017 The Author(s)
Published by S. Karger GmbH, Freiburg 
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 Introduction 
 Obesity is a global health problem with increasing rates not only in the industrialized 
world but also, and more pronounced, in many developing countries  [1, 2] . Its main cause is 
the modern lifestyle with an excess intake of calories, e.g. via energy-dense food, and a lack 
of physical activity. The associated risk of comorbidities, an impaired quality of life, and an 
increased mortality rate in obese persons emphasize the need for concerted efforts to 
prevent and treat obesity more effectively. However, the currently used approaches to 
manage obesity by lifestyle intervention are insufficient to reduce excess body weight and 
its adverse consequences adequately. Additional and more effective treatment options are 
urgently needed. 
 During the past decades, there were many attempts to develop weight-lowering agents 
for an adjunct treatment of obesity in addition to lifestyle counseling. Many studies showed 
disappointing results, and many drugs had to be withdrawn due to side effects or lack of a 
positive benefit-risk ratio  [3–5] . At present, very few anti-obesity agents are available. In 
Europe, only two weight-lowering drugs are on the market. Both orlistat and the more 
recently approved GLP-1 mimetic liraglutide at a dosage of 3 mg/day were shown to have a 
modest to moderate weight-lowering potency in randomized controlled trials  [6–8] . In 
Germany, some agents from the era of amphetamines and amphetamine-like agents are still 
available and used. The latter drugs were launched more than 40 years ago before strict rules 
for the approval of weight-lowering agents were introduced and before specific clinical 
studies became mandatory for approval.
 One of these older drugs is cathine or nor-pseudoephedrine. It was originally launched 
in the 1970s for the short-term treatment of diet-related obesity. Cathine is an alkaloid orig-
inally isolated from khat leaves grown in East Africa and the Arab peninsula and is a stable 
metabolite of cathinone, which is the main psychoactive alkaloid of kath  [9–12] . The pharma-
cological action of cathine includes central (anorexia, increased alertness, increased sensory 
stimulation, hyperthermia) as well as peripheral effects (increased respiration and heart rate, 
rise of blood pressure, constipation, urine retention)  [11] . 
 So far, there are only limited human data on the effect of cathine as a weight-lowering 
agent that originate from inadequate and poorly controlled trials  [13, 14] . The aim of this 
study was, therefore, to assess the efficacy and safety of cathine for weight loss in obese 
subjects in a randomized controlled clinical trial. As older reports stress the development of 
tolerance to the action of cathine due to a depletion of neurotransmitters in the central 
nervous system, it was of particular interest to investigate its effect up to 24 weeks.
 Patients and Methods 
 Design and Patients 
 A multicenter, double-blind, randomized, placebo-controlled dose-finding study was performed in 241 
obese patients over 24 weeks. Eligibility criteria included male or female gender, an age between 18 to 65 
years, a BMI of 30–40 kg/m 2 or of 27–29.9 kg/m² with at least one coexisting risk factor (type 2 diabetes 
mellitus and/or lipid disorder). Exclusion criteria were a systolic blood pressure exceeding 160 mm Hg, a 
diastolic blood pressure exceeding 100 mm Hg and/or a heart rate exceeding 100/min after 5 min of rest in 
a sitting position. Patients were also excluded if they took sympathomimetic or psychotropic drugs (including 
antidepressants, neuroleptics, sedatives, centrally acting antihypertensives) or received β-blockers, insulin 
therapy or any other medication which might alter body weight or interfere with the absorption, metabolism 
or excretion of cathine. Pre-existing conditions that precluded participation in this study were amongst 
others cardiovascular and cerebrovascular diseases, pulmonary hypertension, neuropsychiatric disorders, 
impaired liver or kidney function, chronic obstructive pulmonary disease, bronchial asthma, insomnia, 
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 At the screening visit, the medical history of each patient was recorded followed by physical exami-
nation as well as electrocardiographic and laboratory assessment. In women, a pregnancy test was performed. 
All patients received detailed information about the study protocol and provided written informed consent. 
The study was conducted at four academic and private trial sites in Germany in accordance with the Inter-
national Conference on Harmonization Good Clinical Practice Guidelines. The study protocol was approved 
by the Ethics Committees of the participating centers.
 Treatment and Study Medication 
 After a 2-week placebo run-in period, patients were randomly allocated to four treatment arms. Once 
daily, they received a defined solution containing 0, 16, 32 or 53.3 mg cathine hydrochloride (Antiadi-
positum X-112 T ® now renamed Alvalin ® ; RIEMSER Pharma, Riems, Germany). After 12 weeks, there was 
a comprehensive assessment of the tolerability of the drug, and if there were no serious drug-related 
adverse events the administration of the drug was continued for another 12 weeks, resulting in a total 
treatment period of 24 weeks. Regular visits at the study centers were held every 2 weeks over the entire 
period of treatment. In addition, follow-up visits were performed at weeks 28 and 52, i.e. 4 and 28 weeks 
after termination of active treatment. At each visit, anthropometric variables, electrocardiography, and 
other outcome variables including potential adverse events were assessed. Anthropometric measurements 
(body weight, waist circumference) were performed using established procedures in a standardized 
manner. 
 Lifestyle Program 
 Each patient, independent of group allocation, received structured counseling sessions using an estab-
lished and validated intervention program  [15] which was adapted to the specific requirements of the study 
design. In addition, the recommendations were individually tailored based on the analysis of dietary 
protocols. The aim was to achieve an energy deficit of 500–600 kcal/day. The level of daily physical activity 
was assessed using a pedometer. Patients were recommended to increase their physical activity up to 5,000 
to 10,000 steps/day, depending on baseline activity using a pedometer for self-monitoring.
 Study End Points 
 Primary outcome variable of this study was the change in body weight after 24 weeks of treatment.
 Secondary end points included percentage of patients with weight loss > 5% and > 10%, changes of BMI, 
waist circumference (WC), waist-hip ratio (WHR), serum lipids and glucose, adverse event outcome as well 
as changes in blood pressure, heart rate and QT interval. 
 Blood Collection and Biochemical Analyses 
 Blood was taken from patients in the fasted state at baseline and then 4, 8, 12, 16, 20, and 24 weeks after 
start of treatment. TSH and HbA1c were evaluated only at baseline. Complete blood count, creatinine, fasting 
glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, uric acid, transaminases, and γ-GT 
were measured at each time of blood collection. 
 Anxiety and Depression 
 To evaluate symptoms of anxiety and depression patients were asked to complete the Hospital and 
Anxiety and Depression Score (HADS) questionnaire  [16] , at baseline and at several visits during treatment 
and at the 4-week follow-up. The item scores for anxiety and depression were calculated separately and are 
given as subscale scores. 
 Statistical Analysis 
 Statistical analyses were performed using SAS ® 9.2 (SAS Institute Inc., Cary, NC, USA). The main aim of 
the study was to evaluate the efficacy and safety of different doses of cathine compared to placebo for weight 
loss and maintenance of reduced weight when administrated in conjunction with a lifestyle modification 
program over a period of 24 weeks in diet-induced obese patients. The primary efficacy measure was the 
reduction of body weight upon the different treatment doses of cathine compared to placebo at the end of 
the study. ANCOVA with weight loss after 24 weeks as dependent variable, treatment group as independent 
variable, and baseline weight as covariate was used for statistical primary target analysis. Thereafter, the 
significant influence of treatment group on weight loss compared to placebo was analyzed by a Tukey-
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serum lipids, fasting glucose, BMI, blood pressure, heart rate, and the proportions of patients achieving a 
weight loss of >5% and >10% at the end of study.
 The sample size of 60 patients/treatment group (240 patients in total) was calculated by assuming a 
clinically relevant difference of d = 3 kg, a standard deviation of σ = 3.2 kg, a β-level of 0.10, and a dropout 
rate of 36%. The SAS ® procedure PROC Plan was used for generating the randomization list.
 All patients with analyzable body weight data at baseline and after 24 weeks of therapy were included 
into the completers’ analysis. In the case of non-completers with body weight data available from the 
beginning of treatment and at least one following study visit, an intention-to-treat (ITT) analysis was applied 
in which missing weight data were replaced by their last observed value (LOCF).
 Results 
 Recruitment and Baseline Data 
 A total of 262 patients were screened, of whom 241 were enrolled in the study ( fig. 1 ). 
During the initial 2-week placebo run-in period, a mean weight loss (± SD) of 0.6 ± 1.5 kg was 
observed. After start of treatment, 4 patients dropped out before the next visit. Therefore, 
data from 237 patients were analyzed on a modified ITT basis. During the active treatment 
period, 59 patients discontinued the study (overall dropout rate 24.9%). Most patients 
dropped out from the placebo group (42.3%). Their main reasons were poor compliance and 
dissatisfaction with weight loss (n = 14). In the 4 groups combined, 12 individuals withdrew 
due to adverse drug reactions (ADRs). Finally, 178 patients completed the trial after 24 weeks. 
This study population was used for a completers’ analysis.
 The baseline characteristics of the 237 patients after randomization are presented in 
 table 1 . Most study patients were women (75.9%). The mean age of all patients was 48.5 ± 
10.4 years, the mean baseline BMI was 34.6 ± 3.4 kg/m². Age and baseline BMI were compa-
rable between the four treatment groups. 12.2% of the patients suffered from type 2 diabetes 
and 34.6% from hypertension with a similar distribution across the four treatment arms 
(data not shown). 
 Primary End Point 
 The mean weight of the patients declined constantly in all active treatment groups until 
the end of the study ( fig. 2 ). Mean weight loss (± SD) after 24 weeks was 6.5 ± 4.2 kg under 
16 mg cathine, 6.2 ± 4.7 kg under 32 mg cathine, and 9.1 ± 5.4 kg under 53.3 mg cathine but 
only 2.4 ± 5.4 kg in the placebo group. The respective levels of weight loss in the completers’ 
analysis were 7.6 ± 3.7 kg under 16 mg cathine (n = 48), 7.0 ± 4.6 kg under 32 mg cathine (n 
= 49), and 9.8 ± 5.6 kg under 53.3 mg cathine (n = 47) versus 3.7 ± 5.0 kg under placebo 
treatment (n = 34). In both types of analysis, weight loss was significantly greater in the active 
treatment groups compared to placebo (each p < 0.02, ANCOVA with Tukey-Kramer Test).
 In the ITT population, mean WC decreased over 24 weeks by 5.4 ± 7.2 cm under 16 mg 
cathine, by 5.1 ± 4.7 cm under 32 mg cathine, by 7.5 ± 5.7 cm under 53.3 mg cathine, and by 
1.6 ± 5.9 cm under placebo treatment ( fig. 2 ). Again, the differences between the three doses 
of cathine and placebo were statistically significant (each p < 0.01, ANCOVA with Tukey-
Kramer Test).
 Figure 3 shows the relative proportions of patients achieving a weight loss of >5% and 
>10% over 24 weeks versus baseline weight for the ITT (LOCF) population. The percentage 
of patients achieving the defined weight reduction was dose-dependent. In the highest cathine 
treatment group, 78.3% lost more than 5% of their initial weight and 41.7% lost more than 
10%. Significantly more individuals in the cathine treatment groups had a weight reduction 
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 Cardiovascular Risk Factors 
 The changes in lipid parameters and fasting plasma glucose over 12 and 24 weeks 
compared to baseline levels are displayed in  table 2 . Total cholesterol and LDL-cholesterol 
were significantly lower in the 16 mg and the 53.3 mg cathine groups after 12 and 24 weeks. 
There were no significant changes in HDL-cholesterol after 12 weeks. HDL-cholesterol signif-
icantly increased after 24 weeks in the placebo group and the group receiving 32 mg cathine. 
Triglycerides were significantly reduced after 12 weeks with 16 mg cathine and after 24 
 Fig. 1. Study flow of patients’ enrollment, randomization, withdrawal from treatment, and analysis.  * 1 pa-
tient dropped out before visit 2;  * * 2 patients dropped out before visit 2. LTFU = Lost to follow-up; DO = drop-
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weeks of treatment with 16 mg, 32 mg, and 53.3 mg cathine, but there was no effect on triglyc-
erides in the placebo  group. Fasting glucose was unchanged with the exception of 24 weeks 
in the group receiving 53.3 mg cathine/day ( table 2 ).
 We analyzed the ITT population (N = 237) for changes in blood pressure and heart rate 
during intervention ( table 3 ). There were no significant decreases in mean systolic and 
diastolic blood pressure after 12 and 24 weeks versus baseline in the 4 study groups. However, 
 Table 1.  Baseline patient characteristics of the ITT population (n = 237)*
Characteristic Placebo









Age, years 47.5 ± 11.0 48.8 ± 10.4 48.5 ± 10.3 49.3 ± 10.2 48.5 ± 10.4
Gender, M/F 17/42 10/47 21/40 9/51 57/180
Height, cm 171.0 ± 8.3 167.0 ± 7.5 170.3 ± 8.0 168.5 ± 7.8 169.2 ± 8.0
Weight, kg 101.6 ± 15.6 95.5 ± 13.2 102.0 ± 15.0 98.5 ± 14.6 99.4 ± 14.8
BMI, kg/m² 34.6 ± 3.3 34.1 ± 3.4 35.0 ± 3.4 34.6 ± 3.6 34.6 ± 3.4
HC, cm 119.2 ± 10.0 116.4 ± 15.5 119.7 ± 9.2 119.1 ± 9.8 119.1 ± 9.7
WC, cm 109.8 ± 12.1 106.6 ± 10.8 109.0 ± 12.1 107.6 ± 11.3 108.3 ± 11.6
Systolic BP, mm Hg 128.0 ± 13.9 130.8 ± 15.2 128.2 ± 13.5 133.8 ± 15.9 130.2 ± 14.7
Diastolic BP, mm Hg 82.3 ± 7.3 84.4 ± 7.6 83.5 ± 8.8 85.9 ± 8.9 84.0 ± 8.2
Heart rate, bpm 68.7 ± 11.0 69.7 ± 10.0 69.3 ± 12.4 67.2 ± 9.9 68.7 ± 10.9
Total cholesterol, mmol/l 5.6 ± 1.1 5.9 ± 1.0 5.5 ± 1.1 5.7 ± 0.9 5.7 ± 1.0
LDL-cholesterol, mmol/l 3.5 ± 1.0 3.7 ± 0.9 3.3 ± 0.9 3.6 ± 0.9 3.5 ± 0.9
HDL-cholesterol, mmol/l 1.4 ± 0.4 1.5 ± 0.4 1.4 ± 0.4 1.5 ± 0.4 1.5 ± 0.4
Triglycerides, mmol/l 1.6 ± 0.8 1.7 ± 0.9 1.8 ± 0.9 1.6 ± 0.8 1.7 ± 0.8
Fasting glucose, mmol/l 5.4 ± 1.7 5.1 ± 0.8 5.6 ± 1.3 5.5 ± 1.7 5.4 ± 1.4
HbA1c, % 2.7 ± 0.1 2.7 ± 0.0 2.7 ± 0.1 2.7 ± 0.1 2.7 ± 0.1
 BP = Blood pressure; HC = hip circumference; M/F = male/female; WC = waist circumference.
*Data are presented as mean ± SD.
 Table 2.  Changes in obesity-associated risk factors from baseline value after 12 and 24 weeks (mean ± SD of remaining patients 
at time points)
Change after 12 weeks
(n = 211)
Change after 24 weeks
 (n = 178)
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 Fig. 2. Changes in weight (kg) and waist circumference (cm) (mean ± SD) in the ITT (LOCF) population (n = 
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in those participants with elevated blood pressure at baseline (systolic blood pressure  ≥ 140 
mm Hg and < 160 mm Hg and/or diastolic blood pressure  ≥ 90 mm Hg and < 100 mm Hg), a 
significant decrease in blood pressure was observed (systolic blood pressure –8.1 ± 11.7 mm 
Hg, diastolic blood pressure –3.7 ± 7.7 mm Hg, p < 0.05 vs. baseline, ITT analysis, patients 
under cathine combined, n = 71). 
 Treatment with cathine produced a moderate, dose-dependent, but not significant 
increase in heart rate. After 24 weeks, the mean increase in heart rate was 1.2 ± 8.7 bpm under 
16 mg cathine, 5.8 ± 11.4 bpm under 32 mg cathine, and 6.2 ± 10.3 bpm under 53.3 mg cathine. 
In the placebo group a modest decrease of heart rate by 1.4 ± 10.3 bpm was observed ( fig. 4 ). 
Comparable results were obtained in the completer population (data not shown). In addition, 
electrocardiography analysis performed in regular intervals in all patients did not reveal any 
abnormalities (data not shown).
 Fig. 3. Patients who lost >5% and >10% of their baseline body weight at week 24 (ITT (LOCF) population, 
n = 237). 
 Table 3.  Changes in blood pressure and heart rate (mean ± SD) after 24 weeks for the ITT (LOCF) population, 
n = 237
 Change after 24 weeks (n = 237)
placeb o 16 mg cathine 32 mg cathine 53.3 mg cathine
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 Anxiety and Depression Score 
 The HADS depression subscore improved significantly from baseline to the assessment 
after 24 weeks. Improvements were seen in all groups. With the exception of the 53.3 mg 
group, significant changes for the anxiety subscores were not observed between any of the 
assessments (supplementary table 1, available at  http://content.karger.com/ProdukteDB/
produkte.asp?doi=478098 ). 
 Adverse Events and Tolerability 
 During the clinical trial, a total of 243 adverse events were documented. No suspected 
unexpected serious adverse reactions were reported. Eight of the adverse events were 
serious, but without any causal relationship to the study medication. 60 adverse events were 
classified as non-serious ADRs. These reactions included, amongst others, cardiovascular 
events (e.g. tachycardia, increase in blood pressure) as well as events related to the central 
nervous system (e.g. restlessness, sleep disorder, depression). The number of ADRs increased 
in proportion to the cathine dosage the patients received.  Table 4 presents all ADRs occurring 
in the treatment as well as in the placebo group. Due to ADRs, a total of 12 patients dropped 
out from the study ( table 4 ).
 Follow-Up after Intervention 
 A total of 141 patients who completed the clinical trial attended a follow-up visit at week 
4 or 28 after stopping the active intervention. In this period, patients had received neither 
study medication nor any other supportive measures to maintain their weight loss. The mean 
weight increased in all groups (supplementary fig. 1, available at  http://content.karger.com/
 Fig. 4. Changes in heart rate over 24 weeks under treatment with cathine or placebo (mean ± SD) (com-
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ProdukteDB/produkte.asp?doi=478098 ), but still remained below baseline. Weight regain in 
the cathine groups was slightly higher than in the placebo group. During the follow-up period, 
no serious adverse reactions were reported (data not shown).
 Discussion 
 The present study is the first phase II dose-finding study to investigate the effect of 
cathine on weight reduction in obese patients. The results suggest that the drug has a signif-
icant weight-reducing effect for all of the doses tested. The 53.3 mg dose was more effective 
 Table 4.  Total ADRs for each treatment group and ADRs leading to drop out of patients before the end of the 
study




Hypertension 1 1 3
Ischemia 1
Ventricular extrasystoles 1
ECG QT prolonged 1
Dizziness 1
Syncope 1
Headache 1 1 1
Restlessness 1 1 1 3
Psychomotor hyperactivity 1




Dry mouth 2 2
Hyperhidrosis 2
Hepatic enzyme increased 1
Transaminases increased 1
GGT increased 1
Blood glucose increased 1
Hyperglycemia 1
Weight increased 1








Total reported ADRs 9 11 14 26
Drop outs due to an ADR 3a 3b 4c 2d
 a1× headache, 1× depression, 1× hyperglycemia.
b1× dizziness, 1× GGT increased, 1× hypersensitivity.
c1× sleep disorder, 1× hot flush, 1× hepatic enzyme  increased, 1× transaminases increased.
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than the two lower doses. At the maximum dosage, mean weight loss was 9.1 kg as compared 
to 2.4 kg under placebo treatment after 24 weeks. Surprisingly, the weight loss at doses of 16 
and 32 mg/day was similar. This could be due to a lower compliance to the concomitant diet 
in the 32 mg group, but cannot be fully explained. 
 All patients received an intensive multimodal lifestyle modification program comprising 
an energy-restricted diet and an increase in physical activity. The principal finding of this 
randomized controlled trial on cathine was that this agent is effective and rather safe to 
support weight loss in obese subjects over this short-term period. To date, our knowledge on 
the weight-lowering potential of cathine is mainly based on very small studies with a limited 
number of patients in the 1970s  [13, 14] , although cathine has been used for the treatment of 
obesity for more than 40 years. In Germany, nearly 1 million obese individuals were treated 
with cathine in the past 10 years. The incidence of reported ADRs was low – less than 40 spon-
taneous case reports from healthcare professionals were collected in this time  [17] . However, 
it should be stressed that substantial underreporting of ADRs in primary care is a known 
problem of such registries based on self-reporting.
 As expected from a drug with sympathomimetic action, cathine increased heart rate, with 
a mean increase at the two highest concentrations of about 6 bpm. The reduction of blood 
pressure was smaller than expected by the extent of weight loss, but was seen in those with 
moderately elevated blood pressure at baseline. This observation is similar to the experience 
with sibutramine, which also exhibits a rather modest decrease in blood pressure, particu-
larly in those patients with elevated blood pressure  [15, 18] . Electrocardiography analysis 
performed in regular intervals in all patients did not reveal any abnormalities. It is important 
to note that high-risk patients were excluded. Therefore, the safety data observed in this trial 
are not representative for the general obese population, and additional larger studies with 
longer exposure are required to obtain more reliable information.
 After premature termination of the SCOUT study due to the adverse long-term effect of 
sibutramine on the cardiovascular system and the withdrawal of rimonabant, assessment of 
potential adverse events is of crucial importance for any centrally acting weight-lowering 
drug. The results of this study indicate that cathine has a similar risk profile as sibutramine 
with regard to activation of the sympathetic nervous system. Nevertheless, even in the group 
receiving the highest dose of cathine no serious adverse reactions were observed. No signs of 
any kind of misuse or abuse were noted. Thus, no new safety issues were identified during 
this clinical trial, although the sample size was too small to exclude other rare adverse events. 
 According to the literature, it is assumed that cathine has only a transient weight-lowering 
activity due to the development of tolerance or tachyphylaxia. Therefore, the original recom-
mendation was to use cathine only for short treatment intervals of 4–6 weeks. This study was 
designed to examine the efficacy of cathine treatment for up to 24 weeks in a controlled 
clinical setting. Our results indicate that there is no attenuation or even loss of efficacy 
concerning weight reduction over this period. Weight loss continued, even between week 12 
and 24. Thus, this trial suggests that administration of cathine may have a longer duration of 
action and may be similar to noradrenergic drugs such as sibutramine and phentermine. 
Nevertheless, in view of the chronic nature of obesity and the potential need for much longer 
treatment, additional studies are required to investigate the efficacy and safety of the 
compound over longer periods.
 We also monitored obesity-associated risk factors such as glucose and lipid metabolism. 
In earlier reports, it was argued that cathine and related compounds from khat leaves would 
deteriorate glucose tolerance and lipid metabolism, but there is also a report showing a bene-
ficial effect  [11] . In our study, there was no unfavorable effect of cathine at any dosage on the 
measured parameters of glucose and lipid metabolism. Even in the subgroup of people with 
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has to be noted that the current study is too small to clarify the metabolic effects of this 
compound.
 Although the results of this trial may give some preliminary answers to old questions, 
they may also raise some new ones. If cathine has a potential for weight loss as indicated by 
this study, what is the best way of application and treatment duration, and what is the long-
term benefit-risk ratio? Although the compound appears to be tolerated well, the question 
may arise as to whether it may convey similar risks for cardiovascular complications as 
reported for sibutramine due to its indirect sympathomimetic action. This is still an open 
question, as obese patients with elevated cardiovascular risk were intentionally excluded.
 In conclusion, the results of this dose-finding study suggest that cathine has a potential 
for adjunct pharmacological treatment of obesity with an acceptable risk profile. In view of 
the still growing obesity epidemic, effective and safe treatment options are urgently needed, 
and based on the findings of this study cathine may deserve a more comprehensive explo-
ration in larger clinical trials.
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